Report of Foreign Issuer (6-k)
October 24 2019 - 08:01AM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Form 6-K
Report of Foreign Private Issuer
Pursuant to Rule 13a-16 or 15d-16
under the Securities Exchange Act of 1934
For the month of: October 2019
Commission file number: 001-36578
ENLIVEX THERAPEUTICS LTD.
(Translation of registrant’s name into
English)
14 Einstein Street, Nes Ziona, Israel 7403618
(Address of principal executive offices)
Indicate by check mark whether the registrant
files or will file annual reports under cover of Form 20-F or Form 40-F.
Form
20-F x Form
40-F ¨
Indicate
by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulations S-T Rule 101(b)(1): ¨
Indicate
by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulations S-T Rule 101(b)(7): ¨
On October 22, 2019,
the Board of Directors of Enlivex Therapeutics Ltd., a company organized under the laws of the State of Israel (the “Company”),
appointed Dr. Oren Hershkovitz to serve as the Company’s Chief Executive Officer, effective November 16, 2019. Dr. Schmuel
Hess will continue to serve as Chief Executive Officer until such date.
Dr. Hershkovitz, 42,
is a biotech executive who has extensive experience in the development and management of global pharmaceutical programs from preclinical
stage through phase 3 clinical trials. Since 2011, Dr. Hershkovitz has been employed by OPKO Biologics, Ltd. (formerly Prolor Biotech
Ltd.), first as Vice President of R&D from 2011 to 2014, then as Co-General Manager until 2017 and subsequently as General
Manager from 2017 through the present. Dr. Hershkovitz received his Ph.D. from Ben Gurion University of the Negev in 2008.
Upon commencement of
his employment with the Company, Dr. Hershkovitz will receive an annual salary of NIS 65,000 and options to purchase 150,000 ordinary
shares of the Company, vesting over four years. Dr. Hershkovitz will otherwise be entitled to receive such benefits of employment
as are generally available to the Company’s other executive officers, as described in the Company’s Annual Report on
Form 20-F, as filed with the Securities and Exchange Commission on April 30, 2019.
Other than as described
in this Report on Form 6-K, there are no arrangements or understandings between Dr. Hershkovitz and any other person pursuant to
which Dr. Hershkovitz was selected as an officer of the Company. Since the beginning of the Company’s last fiscal year, the
Company has not engaged in any transaction, or any currently proposed transaction, in which Dr. Hershkovitz had or will have a
direct or indirect material interest in which the amount involved exceeded or would exceed $120,000.
This Report on Form
6-K of the Company is incorporated by reference into the Company’s registration statements on Form S-8 (File Nos. 333-203114
and 333-210459) and Form F-3 (File Nos. 333-232009 and 333-232413) filed with the Securities and Exchange Commission.
SIGNATURES
Pursuant to the requirements of the Securities
Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly
authorized.
|
Enlivex Therapeutics Ltd.
|
|
(Registrant)
|
|
|
|
By:
|
/s/ Shai Novik
|
|
Name:
Title:
|
Shai Novik
Executive Chairman
|
Date: October 23, 2019
Enlivex Therapeutics (NASDAQ:ENLV)
Historical Stock Chart
From Feb 2024 to Mar 2024
Enlivex Therapeutics (NASDAQ:ENLV)
Historical Stock Chart
From Mar 2023 to Mar 2024